NEOS Investment Management LLC Has $23.56 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Posted by on Sep 5th, 2026

NEOS Investment Management LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 13.6% in the second quarter, HoldingsChannel.com reports. The firm owned 78,274 shares of the biopharmaceutical company’s stock after purchasing an additional 9,401 shares during the quarter. NEOS Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $23,563,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ALNY. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Golden State Wealth Management LLC increased its stake in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the period. Finally, Manchester Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.6%

NASDAQ ALNY opened at $266.11 on Friday. The business has a fifty day moving average price of $259.25 and a two-hundred day moving average price of $291.61. The stock has a market capitalization of $35.61 billion, a PE ratio of 49.46 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the company posted ($0.51) EPS. The company’s revenue for the quarter was up 66.9% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of a number of recent analyst reports. Sanford C. Bernstein reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. BMO Capital Markets reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Finally, Oppenheimer reduced their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.14.

View Our Latest Report on Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Read More

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.